Ofatumumab (OMBI157) is used for the treatment of multiple sclerosis (MS) and is marketed under the brand name Kesimpta; it can also serve as a salvage therapy in cases where rituximab treatment is ineffective and as a first-line treatment for lymphoid malignancies.